

Product Data Sheet

Product Name: Altrenogest

Cat. No.: GC13297

Chemical Properties

Cas. No. 850-52-2

Chemical Name (8S,13S,14S,17R)-17-hydroxy-13-methyl-17-prop-2-enyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

SMILES CC12C=CC3=C4CCC(=O)C=C4CCC3C1CCC2(CC=C)O

Formula $C_{21}H_{26}O_2$

M.Wt 310.43


Solubility $\geq 14.4\text{mg/mL}$ in DMSO

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

Altrenogest (Allyltrenbolone) is a progestogen structurally related to veterinary steroid trenbolone.

Altrenogest (Allyltrenbolone) is a progestogen structurally related to veterinary steroid trenbolone. Treatment of embryo-recipient mares with Altrenogest (Allyltrenbolone) appears to be beneficial in extending the degree of donor-recipient synchrony required for successful embryo transfer[1]. The oil and gel Altrenogest (Allyltrenbolone) preparations are equally effective in modulating estrous behavior and time to estrus and ovulation. Altrenogest (Allyltrenbolone) treatment started late in diestrus appears to result in a high incidence of ovulation during treatment and when luteolysis and ovulation occur during treatment; the subsequent luteal phase is frequently prolonged due to failure of

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

regression of the CL[2].

References:

- [1]. Parry-Weeks, L.C. and D.W. Holtan, Effect of altrenogest on pregnancy maintenance in unsynchronized equine embryo recipients. J Reprod Fertil Suppl, 1987. 35: p. 433-8.
- [2]. Daels, P.F., et al., Persistence of the luteal phase following ovulation during altrenogest treatment in mares. Theriogenology, 1996. 46(5): p. 799-811.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA